



CPIC Survey Results

Demographics




Demographics




Demographics


What percent of your time is related to work involving pharmacogenetics?



Initial prioritization considerations for new gene/drug groups

(may change over time as evidence and experience accumulates)





Top 10 (Highest priority-all participants)

- CYP2C19 and proton pump inhibitors (i.e., esomeprazole, omeprazole, etc.)
- CYP2D6 and antipsychotics
- CYP2D6 and other antidepressants (mirtazapine, venlafaxine, duloxetine, vortioxetine)
- UGT1A1 and irinotecan
- CYP2D6 and ADHD drugs (atomoxetine, methylphenidate)
- CYP2D6 and beta blockers (carvedilol, metoprolol, propranolol, timolol)
- CYP2C19 and benzodiazepines (clobazam, diazepam)
- CYP2B6 and methadone
- CYP2C9 and NSAIDs (celecoxib, flurbiprofen, diclofenac)
- CYP2D6 and antiarrhythmics (quinidine, flecainide, propafenone)

Top 10 (Highest priority-practicing physicians)

- CYP2D6 and antipsychotics CYP2C19 and proton pump inhibitors (i.e., esomeprazole, omeprazole, etc.)
- CYP2D6 and other antidepressants (mirtazapine, venlafaxine, duloxetine, vortioxetine)
- UGT1A1 and irinotecan
- CYP2C19 and benzodiazepines (clobazam, diazepam)
- CYP2D6 and ADHD drugs (atomoxetine, methylphenidate)
- CYP2D6 and beta blockers (carvedilol, metoprolol, propranolol, timolol)
- CYP2C9 and NSAIDs (celecoxib, flurbiprofen, diclofenac)
- CYP2D6 and antiarrhythmics (quinidine, flecainide, propafenone)
- CYP2D6 and dextromethorphan